What BEONE MEDICINES does

BeOne Medicines is a global oncology therapeutics company that develops and commercializes treatments for blood cancers and solid tumors, with a pipeline spanning small molecules, biologics, antibody drug conjugates (ADCs), and protein degradation via CDACs. Its three internally developed approved medicines—Brukinsa (zanubrutinib), a BTK inhibitor; Tevimbra (tislelizumab), a PD-1 inhibitor; and tarlatamab, a bispecific T-cell engager developed with Amgen—are sold across 80+ countries, supported by a clinical operations footprint spanning 45+ countries and 30,000+ enrolled patients. The company supplements internal R&D with licensing and collaboration deals, including a $1.9B-milestone agreement with Huahui Health for the HH160 trispecific antibody and combination-trial partnerships with Senhwa Biosciences.

BeOne generates revenue through two streams: direct pharmaceutical product sales of approved oncology medicines to healthcare providers and national health systems, and licensing/milestone payments including upfront fees, development/regulatory/sales milestones, and tiered royalties on partnered products. Distribution runs through field medical and senior medical advisors engaging healthcare providers directly, supplemented by reimbursement negotiations with health technology assessment bodies (NICE, SMC, NCPE, Ireland HSE). The company is publicly traded under ticker ONC as the rebrand of BeiGene, operates across six continents with approximately 12,000 employees including 1,200+ in research, and pursues a vertical segmentation approach serving haematology and solid tumour patient populations globally.

The company's competitive positioning rests on scientific execution speed, broad modality coverage, and global commercial reach. Recent strategic activity—including tarlatamab's China approval, tislelizumab's Irish reimbursement, FDA Orphan Drug Designation for a hepatocellular carcinoma candidate, and the Huahui Health trispecific antibody deal—indicates continued offensive expansion across geographies, modalities, and indications rather than defensive retrenchment.

Name

BEONE MEDICINES

Legal name

BeOne Medicines I GmbH

Website

https://beonemedicines.co.uk

Company type

Public

Founded year

2018

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

BeOne Medicines is a global oncology company that develops and commercializes cancer therapeutics, including the approved drugs Brukinsa, Tevimbra, and tarlatamab, across 80+ countries for blood and solid tumor patients.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

Keywords

• Oncology therapeutics
• Cancer drug development
• Immuno-oncology drugs
• Hematologic malignancy treatment
• Clinical trial research

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Pharmaceutical Product Sales: BeOne Medicines generates revenue through the sale of internally developed oncology medicines globally, including Brukinsa (zanubrutinib), tislelizumab (marketed as Tevimbra), and tarlatamab. Products are sold in 80+ countries following regulatory approvals.
2. Licensing and Milestone Payments: Revenue generated through licensing agreements including upfront payments, option exercise payments, development/regulatory/sales milestones, and tiered royalties on net sales from partnered products like HH160.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

BeOne Medicines is a global oncology company that discovers, develops, manufactures, and commercializes innovative cancer therapeutics for both hematologic malignancies and solid tumors. The company's portfolio includes three internally developed approved medicines — Brukinsa (zanubrutinib, a BTK inhibitor), Tislelizumab (Tevimbra, a PD-1 inhibitor), and Tarlatamab (a bispecific T-cell engager) — supported by a deep pipeline of candidates including HH160 and BGB-16673, with regulatory approvals across 80+ countries.

Product overview

BeOne Medicines is a global oncology company offering a portfolio of approved and investigational cancer medicines. The company's core products include Brukinsa (zanubrutinib), a BTK inhibitor approved across 80+ countries; Tislelizumab (Tevimbra), a PD-1 inhibitor for solid tumors; and tarlatamab, a bispecific T-cell engager for small cell lung cancer. Pipeline candidates include HH160, a trispecific antibody targeting PD-1/CTLA-4/VEGF-A for oncology, and BGB-16673 in Phase 1/2 trials for marginal zone lymphoma. The company operates clinical trials across 45+ countries and regions with approximately 30,000 patients enrolled.

Differentiator

Problem solved

Functional benefit

Brands

• Tevimbra: Brand name for tislelizumab, a PD-1 inhibitor approved for advanced oesophageal cancer and other indications.
• Brukinsa

Products and services

• Brukinsa (zanubrutinib) A BTK (Bruton's tyrosine kinase) inhibitor approved for the treatment of various hematologic malignancies, marketed across 80+ countries as one of BeOne's three internally developed medicines.
• Tislelizumab (Tevimbra) A PD-1 inhibitor immunotherapy drug for treating advanced solid tumors including oesophageal squamous cell carcinoma and multiple other malignancies, marketed under the brand name Tevimbra.
• Tarlatamab A bispecific T-cell engager approved in China for adult patients with extensive-stage small cell lung cancer whose disease has progressed after chemotherapy; BeOne serves as development and commercialization partner for Amgen in the Chinese market.
• HH160 A novel trispecific antibody targeting PD-1, CTLA-4, and VEGF-A for oncology immunotherapy, licensed globally from Huahui Health and utilizing the PolyBoost multispecific antibody platform; BeOne holds exclusive worldwide rights to develop, manufacture, and commercialize.
• BGB-16673 A drug candidate in Phase 1/2 clinical development for marginal zone lymphoma treatment, part of BeOne's expanding pipeline of targeted oncology therapies using protein degradation approaches.

Quantifiable outcome

• Phase 3 RATIONALE-306 trial demonstrated median overall survival of 17.2 months vs 10.6 months with chemotherapy alone for tislelizumab in advanced oesophageal squamous cell carcinoma
• +1 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Huahui HealthcoreStrategic or Co-development Partner · 5 May 2026Global exclusive option, license and collaboration agreement for HH160, a novel trispecific antibody targeting PD-1, CTLA-4, and VEGF-A for oncology immunotherapy. BeOne Medicines pays USD 20 million upfront, USD 100 million upon option exercise, and up to USD 1.9 billion in milestones plus tiered royalties. Collaboration leverages Huahui Health's PolyBoost platform with BeOne's global oncology development expertise.
• Senhwa BiosciencesminorStrategic or Co-development Partner · 5 May 2026Clinical trial collaboration evaluating Senhwa's first-in-class investigational drug Pidnarulex (CX-5461) in combination with BeOne Medicines' PD-1 inhibitor tislelizumab across multiple advanced solid tumors including pancreatic cancer, colorectal cancer, and melanoma.
• AmgencoreStrategic or Co-development Partner · 12 April 2026Development and commercialization partnership for tarlatamab, a bispecific T-cell engager. BeOne Medicines serves as the development and commercialization partner in China, where the therapy received regulatory approval from China's National Medical Products Administration for treating extensive-stage small cell lung cancer.

Scale indicators9 records

Recent moves6 records

Expansion highlights7 records

Broad incumbents

• Pfizer: Operates a broad oncology portfolio including PD-1/PD-L1 inhibitors, ADCs, and hematology assets. Pfizer is a broader incumbent rather than a focused peer, but competes in many of the same solid-tumor and hematology indications as BeOne.
• Roche: Global oncology leader with checkpoint inhibitors (Tecentriq), HER2/oncology ADCs, and a deep hematology franchise. Competes with BeOne across both immuno-oncology and ADC modalities and serves as a benchmark for global oncology commercial scale.
• Johnson & Johnson: Significant oncology presence in multiple myeloma (Darzalex, Carvykti) and prostate cancer (Erleada, Akeega). J&J competes with BeOne in hematology and is a benchmark for global commercial reach in oncology.
• Gilead Sciences: Oncology franchise anchored by Trodelvy (ADC) and growing hematology assets post-Immunomedics acquisition. Gilead competes with BeOne in solid-tumor ADC space and shares the multi-modality innovator playbook.
• Novartis: Major oncology player with radioligand therapy (Pluvicto), targeted therapies (Kisqali, Scemblix), and CAR-T (Kymriah). Comparable to BeOne as a globally diversified innovator with multi-modality oncology ambitions.

Direct peers

• AbbVie: Markets Imbruvica (ibrutinib, BTK inhibitor) and Venclexta (BCL-2) — direct competitors to BeOne's Brukinsa in hematologic malignancies. AbbVie's established hematology commercial infrastructure is the primary incumbent BeOne must displace in BTK-driven indications.
• Merck & Co. Keytruda (pembrolizumab) is the global PD-1 standard of care and the most direct competitive threat to tislelizumab across oncology indications. Merck's oncology commercial reach and pipeline depth make it the primary benchmark for BeOne's IO franchise trajectory.
• AstraZeneca: Global oncology major with a directly overlapping portfolio across PD-1/PD-L1 inhibitors (Imfinzi), ADCs (Enhertu, Datroway), and targeted therapies across hematology and solid tumors. AstraZeneca competes head-to-head with BeOne in immuno-oncology and ADC modalities and recruits from a similar talent base (per the Anurag Gupta hire background).
• Bristol Myers Squibb: Operates Opdivo (PD-1) and a leading hematology/oncology franchise (Pomalyst, Reblozyl, Empliciti). BMS directly competes with BeOne in both PD-1 solid-tumor indications and B-cell hematologic malignancies targeted by Brukinsa.
• Amgen: Tarlatamab development partner for the China market and a broad oncology/biologics player (Blincyto, Lumakras, Imdelltra). Comparable to BeOne as a large-cap biologics and bispecific T-cell engager developer, and a strategic partner whose priorities directly affect one of BeOne's three core assets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/beonemedicines

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BEONE MEDICINES